Nalaganje...
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were tr...
Shranjeno v:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3383201/ https://ncbi.nlm.nih.gov/pubmed/22611160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-03-418673 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|